Development of lead hammerhead ribozyme candidates against human rod opsin mRNA for retinal degeneration therapy

Experimental Eye Research

Volumn 88, Issue 5, 2009, Pages 859-879

  Abdelmaksoud, Heba E ^a   Yau, Edwin H ^b   Zuker, Michael ^e   Sullivan, Jack M ^a,b,c,d  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^e Research Rensselaer Polytechnic Institute   (United States)

Author keywords

gene therapy; photoreceptor degeneration; retinitis pigmentosa; rhodopsin; ribozyme

Indexed keywords

HAMMERHEAD RIBOZYME; LEAD; OPSIN; RHO FACTOR;

ALLELE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RETINA DEGENERATION; SEQUENCE ANALYSIS;

ADENOVIRIDAE; ALGORITHMS; CELLS, CULTURED; COMPUTATIONAL BIOLOGY; GENE KNOCKDOWN TECHNIQUES; GENE THERAPY; GENETIC VECTORS; HUMANS; MUTATION; RETINAL DEGENERATION; RNA, CATALYTIC; RNA, MESSENGER; ROD OPSINS; TRANSFECTION;

EID: 64849108411     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2008.11.018     Document Type: Article

References (112)

1. Almagor H., and Paigen K. Chemical kinetics of induced gene expression: activation of transcription by noncooperative binding of multiple regulatory molecules. Biochemistry 27 (1988) 2094-2102
2. Amarzguioui M., Brede G., Babale E., Grotli M., Sproat B., and Prydz H. Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes. Nucleic Acids Res. 28 (2000) 4113-4124
3. Barik S. RNAi in moderation. Nat. Biotechnol. 24 (2006) 796-797
4. Beck J., and Nassal M. Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells. Nucleic Acids Res. 23 (1995) 4954-4962
5. Bertrand E., Pictet R., and Grange T. Can hammerhead ribozymes be efficient tools to inactivate gene function?. Nucleic Acids Res. 22 (1994) 293-300
6. Bertrand E., Castanotto D., Zhou C., Carbonnelle C., Lee N.S., Good P., Chatterjee S., Grange T., Pictet R., Kohn D., Engelke D., and Rossi J.J. The expression cassette determines the functional activities of ribozymes in mammalian cells by controlling their intracellular localization. RNA 3 (1997) 75-88
7. Birikh K.R., Berlin Y.A., Soreq H., and Eckstein F. Probing accessible sites for ribozymes on human acetylcholinesterase RNA. RNA 3 (1997) 429-437
8. Brann M.R., and Young W.S. Localization and quantitation of opsin and transducin mRNAs in bovine retina by in situ hybridization histochemistry. FEBS Lett. 200 (1986) 275-278
9. Brauns E.B., and Dyer R.B. Time-resolved infrared spectroscopy of RNA folding. Biophys. J. 89 (2005) 3523-3530
10. Brown K.M., Chu C.-Y., and Rana T.M. Target accessibility dictates the potency of human RISC. Nat. Struct. Mol. Biol. 12 (2005) 469-470
11. Dale T., Smith R., and Serra M.J. A test of the model to predict unusually stable RNA hairpin loop stability. RNA 6 (2000) 608-615
12. Ding Y., and Lawrence C.E. Statistical prediction of single-stranded regions in RNA secondary structure and application to predicting effective antisense target sites and beyond. Nucleic Acids Res. 29 (2001) 1034-1046
13. Ding Y., and Lawrence C.E. A statistical sampling algorithm for RNA secondary structure prediction. Nucleic Acids Res. 31 (2003) 7280-7301
14. Ding Y., Chan C.Y., and Lawrence C.E. Sfold web server for statistical folding and rational design of nucleic acids. Nucleic Acids Res. 32 Suppl. (2004) W135-W141
15. Doherty E.A., and Doudna J.A. Ribozyme structures and mechanisms. Annu. Rev. Biophys. Biomol. Struct. 30 (2001) 457-475
16. Drenser K.A., Timmers A.M., Hauswirth W.W., and Lewin A.S. Ribozyme-targeted destruction of RNA associated with autosomal-dominant retinitis pigmentosa. Invest Ophthalmol. Vis. Sci. 39 (1998) 681-689
17. Fradelizi J., Friederich E., Beckerle M.C., and Golsteyn R.M. Quantitative measurement of proteins by Western blotting with Cy5™-coupled secondary antibodies. Biotechniques 26 (1999) 484-494
18. Gal A., Apfelstedt-Sylla, Janecke A.R., and Zrenner E. Rhodopsin mutations in inherited retinal dystrophies and dysfunctions. Prog. Retin. Eye Res. 16 (1997) 51-79
19. Giddings M.C., Matveeva O.V., Atkins J.F., and Gesteland R.F. ODNBase - a web database for antisense oligonucleotide effectiveness studies. Oligodeoxynucleotides. Bioinformatics 16 (2000) 843-844
20. Gorbatyuk M., Pang J.-J., Thomas Jr. J., Hauswirth W.W., and Lewin A.S. Knockdown of wild-type mouse rhodopsin using an AAV vectored ribozyme as part of an RNA replacement approach. Mol. Vis. 11 (2005) 648-656
21. Gorbatyuk M., Justilien V., Liu J., Hauswirth W.W., and Lewin A.S. Preservation of photoreceptor morphology and function in P23H rats using an allele independent ribozyme. Exp. Eye Res. 84 (2007) 44-52
22. Grimm D., Streetz K.L., Jopling C.L., Storm T.A., Pandey K., Davis C.R., Marior P., Salazar F., and Kay M.A. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441 (2006) 537-541
23. Hendrix C., Anne J., Joris B., Van Aerschot A., and Herdewijn P. Selection of hammerhead ribozymes for optimum cleavage of interleukin 6 mRNA. Biochem. J. 314 (1996) 655-661
24. Herschlag D. Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: more isn't always better. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 6921-6925
25. Hertel K.J., Pardi A., Uhlenbeck O.C., Koizumi M., Ohtsuka E., Uesugi S., Cedergren R., Eckstein F., Gerlach W.L., Hodgson R., and Symons R.H. Numbering system for the hammerhead. Nucleic Acids Res. 20 (1992) 3252
26. Higgs P.G. RNA secondary structure: physical and computational aspects. Quart. Rev. Biophys. 33 (2000) 199-253
27. Homann M., Tabler M., Tzortzakaki S., and Sczakiel G. Extension of helix II and an HIV-1-directed hammerhead ribozyme with long antisense flanks does not alter kinetic parameters in vitro but causes loss of the inhibitory potential in living cells. Nucleic Acids Res. 22 (1994) 3951-3957
28. Hormes R., Homann M., Oelze I., Marschall P., Tabler M., Eckstein F., and Sczakiel G. The subcellular localization and length of hammerhead ribozymes determine efficacy in human cells. Nucleic Acids Res. 25 (1997) 769-775
29. Humphries M.M., Rancourt D., Farrar G.J., Kenna P., et al. Retinopathy induced in mice by targeted disruption of the rhodopsin gene. Nat. Genet. 15 (1997) 216-219
30. Jackson A.L., Burchard J., Schelter J., Nelson Chau B., Cleary M., Lim L., and Linsley P.S. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 12 (2006) 1179-1187
31. Jarvis T.C., Wincott F.E., Alby L.J., McSwiggen J.A., Beigelman L., Gustofson J., DiRenzo A., Levy K., Matulic-Adamic J., Karpeisky A., Gonzalez C., Woolf T.M., Usman N., and Stinchcomb D.T. Optimizing the cell efficacy of synthetic ribozymes: site selection and chemical modifications of ribozymes targeting the proto-oncogene c-myb. J. Biol. Chem. 271 (1996) 29107-29112
32. Kawasaki H., Suyama E., Iyo M., and Taira K. siRNAs generated by recombinant human Dicer induce specific and significant but target site-independent gene silencing in human cells. Nucleic Acids Res. 31 (2003) 981-987
33. Kijas J.W., Cideciyan A.V., Aleman T.S., Pianta M.J., Pearce-Kelling S.E., Miller B.J., Jacobson S.G., Aguirre G.D., and Acland G.M. Naturally occurring rhodopsin mutation in the dog causes retinal dysfunction and degeneration mimicking human dominant retinitis pigmentosa. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 6328-6333
34. Koller A., and Watzig H. Precision and variance components in quantitative gel electrophoresis. Electrophoresis 26 (2005) 2470-2475
35. Kolniak T.A., Yau E.H., Taggart R.T., and Sullivan J.M. Identification of lead candidate ribozymes for human rod opsin therapeutics. Invest. Ophthalmol. Vis. Sci. 48 (2007) 3248 B498
36. Korenbrot J.I., and Fernald R.D. Circadian rhythm and light regulate opsin mRNA in rod photoreceptors. Nature 337 (1989) 454-457
37. Koseki S., Tanabe T., Tani K., Asano S., Shioda T., Nagai Y., Shimada T., Ohkawa J., and Tiara K. Factors governing the activity in vivo of ribozymes transcribed by RNA polymerase III. J. Virol. 73 (1999) 1868-1877
38. Latham M.P., Brown D.J., McCallum S.A., and Pardi A. NMR methods for studying the structure and dynamics of RNA. ChemBioChem 6 (2005) 1492-1505
39. LaVail M.M., Yasumura D., Matthes M.T., Drenser K.A., Flannery J.G., Lewin A.S., and Hauswirth W.W. Ribozymes rescue of photoreceptor cells in P23H transgenic rats: long-term survival and late-stage therapy. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 11488-11493
40. Lem J., Krasnoperova N.V., Calvert P.D., Kosaras B., Cameron D.A., Nicolo M., Makino C.L., and Sidman R.L. Morphological, physiological, and biochemical changes in rhodopsin knockout mice. Proc. Natl. Acad. Sci. U.S.A 96 (1999) 736-741
41. Lewin A.S., Drenser K.A., Hauswirth W.W., Nishikawa S., Yasamura D., Flannery J.G., and LaVail M.M. Ribozyme rescue of photoreceptor cells in transgenic rat model of autosomal dominant retinitis pigmentosa. Nat. Med. 4 (1998) 967-971
42. Li T., Snyder W.K., Olsson J.E., and Dryja T.P. Transgenic mice carrying the dominant rhodopsin mutation P347S: evidence for defective vectorial transport of rhodopsin to the outer segments. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 14176-14181
43. Li T., Sandberg M.A., Pawlyk B.S., Rosner B., Hayes K.C., Dryja T.P., and Berson E.L. Effect of vitamin A supplementation on rhodopsin mutants threonine-17 → methionine and proline-347 → serine in transgenic mice and in cell cultures. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 11933-11938
44. Lieber A., and Strauss M. Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library. Mol. Cell. Biol. 15 (1995) 540-551
45. Lieber A., and Kay M.A. Adenovirus-mediated expression of ribozymes in mice. J. Virol. 70 (1996) 3153-3158
46. Lieber A., He C.-Y., Polyak S.J., Gretch D.R., Barr D., and Kay M.A. Elimination of Hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. J. Virol. 70 (1996) 8782-8791
47. Lima W.F., Monia B.P., Ecker D.J., and Freier S.M. Implication of RNA structure on antisense oligonucleotide hybridization kinetics. Biochemistry 31 (1992) 12055-12061
48. Lin X., Ruan X., Anderson M.G., McDowell J.A., Kroeger P.E., Fesik S.W., and Shen Y. siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res. 33 (2005) 4527-4535
49. Long D.M., and Uhlenbeck O.C. Kinetic characterization of intramolecular and intermolecular hammerhead RNAs with Stem II deletions. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 6977-6981
50. Mathews D.H. Using an RNA secondary structure partition function to determine confidence in base pairs predicted by free energy minimization. RNA 10 (2004) 1178-1190
51. Mathews D.H. Predicting a set of minimal free energy RNA secondary structures common to two sequences. Bioinformatics 21 (2005) 2246-2253
52. Mathews D.H. Revolutions in RNA secondary structure prediction. J. Mol. Biol. 359 (2006) 526-532
53. Mathews D.H., Burkard M.E., Freier S.M., Wyatt J.R., and Turner D.H. Predicting oligonucleotide affinity to nucleic acid targets. RNA 5 (1999) 1458-1469
54. Mathews D.H., et al. Expanded sequence dependence of thermodynamic parameters provides improved prediction of RNA secondary structures. J. Mol. Biol. 288 (1999) 911-940
55. Mathews D.H., Disney M.D., Schroeder S.J., Zuker M., and Turner D.H. Incorporating chemical modification constraints into a dynamic programming algorithm for prediction of RNA secondary structure. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 7287-7292
56. McCaskill J.S. The equilibrium partition function and base pair binding probabilities for RNA secondary structure. Biopolymers 29 (1990) 1105-1119
57. McGinnis J.F., Whelan J.P., and Donoso L.A. Transient, cyclic changes in mouse visual cell gene products during the light-dark cycle. J. Neurosci. Res. 31 (1992) 584-590
58. Millington-Ward S., O'Neill B., Tuohy G., Al-Jandal N., Kiang A.-S., Kenna P.F., Palfi A., Hayden P., Mansergh F., Kennan A., Humphries P., and Farrar G.J. Strategems in vitro for gene therapies directed to dominant mutations. Hum. Mol. Genet. 6 (1997) 1415-1426
59. Mohler W.A., Charlton C.A., and Blau H.M. Spectrophotometric quantitation of tissue culture cell number in any medium. Biotechniques 21 (1996) 260-266
60. Nathans J., Weitz C.J., Agarwal N., Nir I., and Papermaster D.S. Production of bovine rhodopsin by mammalian cell lines expressing cloned cDNA: spectrophotometry and subcellular localization. Vision Res. 29 (1989) 907-914
61. Nakamaye K.L., and Eckstein F. AUA-cleaving hammerhead ribozymes: attempted selection for improved cleavage. Biochemistry 33 (1994) 1271-1277
62. Nathans J., and Hogness D.S. Isolation and nucleotide sequence of the gene encoding human rhodopsin. Proc. Natl. Acad. Sci. U.S.A. 81 (1984) 4851-4855
63. O'Neill B., Millington-Ward S., O'Reilly M., Kiang A.S., Kenna P.F., Humpheries P., and Farrar G.J. Ribozyme-based therapeutic approaches for autosomal dominant retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci. 41 (2000) 2863-2869
64. Onoa B., and Tinoco I. RNA folding and unfolding. Curr. Opin. Struct. Biol. 14 (2004) 374-379
65. Patzel V., and Sczakiel G. Theoretical design of antisense RNA structures substantially improves annealing kinetics and efficacy in human cells. Nat. Biotechnol. 16 (1998) 64-68
66. Patzel V., Steidl U., Kronenwett R., Haas R., and Sczakiel G. A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability. Nucleic Acids Res. 27 (1999) 4328-4334
67. Persengiev S.P., Zhu X., and Green M.R. Nonspecific concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 10 (2004) 12-18
68. Pierce M.E., Sheshberadaran H., Zhang Z., Fox L.E., Applebury M.L., and Takahashi J.S. Circadian regulation of iodopsin gene expression in embryonic photoreceptors in retinal cell culture. Neuron 10 (1993) 579-584
69. Prislei S., Buonomo S.B.C., Michienzi A., and Bozzoni I. Use of adenoviral VAI small RNA as a carrier for cytoplasmic delivery of ribozymes. RNA 3 (1997) 677-687
70. Salehi-Ashtiani K., and Szostak J.W. In vitro evolution suggests multiple origins for the hammerhead ribozyme. Nature 414 (2001) 82-84
71. Scacheri P.C., Rozenblatt-Rosen O., Caplen N.J., Wolfsberg T.G., Umayam L., Lee J.C., Hughes C.M., Shanmugam K.S., Bhattacharjee A., Meyerson M., and Collins F.S. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 1892-1897
72. Scherr M., Rossi J.J., Sczakiel G., and Patzel V. RNA accessibility prediction: a theoretical approach is consistent with experimental studies in cell extracts. Nucleic Acids Res. 28 (2000) 2455-2461
73. Scherr M., and Rossi J.J. Rapid determination and quantitation of the accessibility to native RNAs by antisense oligodeoxynucleotides in murine cell extracts. Nucleic Acids Res. 26 (1998) 5079-5085
74. Sczakiel G., and Tabler M. Computer-aided calculation of the local folding potential of target RNA and its use for ribozyme design. In: Turner P.C. (Ed). Methods in Molecular Biology. Ribozyme Protocols vol. 74 (1997), Humana Press Inc., Totowa, NJ 11-15
75. Sczakiel G., Homann M., and Rittner K. Computer-aided search for effective antisense RNA target sequences of the human immunodeficiency virus type 1. Antisense Res. Dev. 3 (1993) 45-52
76. Semizarov D., Frost L., Sarthy A., Kroeger P., Halbert D.N., and Fesik S.W. Specificity of short interfering RNA determined through gene expression signatures. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 6347-6352
77. Sheldon C.C., and Symons R.H. Mutational analysis of a self-cleaving RNA. Nucleic Acids. Res. 17 (1989) 5679-5685
78. Shibin Q., Coen M., and Terran L. A computational study of off-target effects of RNA interference. Nucleic Acids Res. 33 (2005) 1834-1847
79. Shukla P., and Sullivan J.M. Normal and mutant rhodopsin activation measured with the early receptor current in a unicellular expression system. J. Gen. Physiol. 114 (1999) 609-636
80. Stage-Zimmermann T.K., and Uhlenbeck O.C. Hammerhead ribozyme kinetics. RNA 4 (1998) 875-879
81. Stillman B.W., and Gluzman Y. Replication and supercoiling of simian virus 40 DNA in cell extracts from human cells. Mol. Cell. Biol. 5 (1985) 2051-2060
82. Sullivan J.M., and Shukla P. Time-resolved rhodopsin activation currents in a unicellular expression system. Biophys. J. 77 3 (1999) 1333-1357
83. Sullivan J.M., and Satchwell M.F. Development of stable cell lines expressing high levels of point mutants of human opsin for biochemical and biophysical studies. Methods Enzymol. 315 (2000) 30-58
84. Sullivan J.M., Pietras K.M., Shin B.J., and Misasi J.N. Hammerhead ribozymes designed to cleave all human rod opsin mRNAs which cause autosomal dominant retinitis pigmentosa. Mol. Vis. 8 (2002) 102-113
85. Sullivan J.M., Yau E.H., Taggart R.T., Butler M.C., and Kolniak T.A. Bottlenecks in development of therapeutic post-transcriptional gene silencing agents. Vis. Res. 48 (2008) 453-469 10.1016/j.visres. 2007.09.011 (published on line in 2007)
86. Sullivan J.M., and Taggart R.T. Novel and enhanced approaches to determine local mRNA accessibility. Invest. Ophthalmol. Vis. Sci. 48 (2007) 4605 B442
87. Sung C.-H., Schneider B., Agarwal N., Papermaster D.S., and Nathans J. Functional heterogeneity of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 8840-8844
88. Svensson C., and Akusjarvi G. Adenovirus VA RNAI: a positive regulator of mRNA translation. Mol. Cell. Biol. 4 (1984) 736-742
89. Tang J., and Breaker R.R. Examination of the catalytic fitness of the hammerhead ribozyme by in vitro selection. RNA 3 (1997) 914-925
90. Thompson J.D., Ayers D.F., Malmstrom T.A., McKenzie T.L., Ganousis L., Chowrira B.M., Couture L., and Stinchcomb D.T. Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter. Nucleic Acids Res. 23 (1995) 2259-2268
91. Thirumalai D., Lee N., Woodson S.A., and Klimov D.K. Early events in RNA folding. Annu. Rev. Phys. Chem. 52 (2001) 751-762
92. Tinoco Jr. I., and Bustamante C. How RNA folds. J. Mol. Biol. 293 (1999) 271-281
93. Treiber D.K., and Williamson J.R. Exposing the kinetic traps in RNA folding. Curr. Opin. Struct. Biol. 9 (1999) 339-345
94. Tuerk C., Gauss P., Thermes C., Groebe D.R., Gayle M., Guild N., Stormo G., D'Aubenton-Carafa Y., Uhlenbeck O.C., Tinoco Jr. I., Brody E.N., and Gold L. CUUCGG hairpins: extraordinarily stable RNA secondary structures associated with various biochemical processes. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 1364-1368
95. Tuschl T., and Eckstein F. Hammerhead ribozymes: importance of stem-loop II for activity. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 6991-6994
96. Vaish N.K., Heaton P.A., and Eckstein F. Isolation of hammerhead ribozymes with altered core sequences by in vitro selection. Biochemistry 36 (1997) 6495-6501
97. Watzig H. Quantitation and validation in electrophoresis: definitions and fundamentals. This is available at the following website (2005). http://www.pharmchem.tu-bs.de/waetzig-supportive.html
98. Wu M., and Tinoco Jr. I. RNA folding causes secondary structure rearrangement. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 11555-11560
99. Wuchty S., Fontana W., Hofacker I.L., and Schuster P. Complete suboptimal folding of RNA and the stability of secondary structures. Biopolymers 49 (1999) 145-165
100. Xie Y., Chen X., and Wagner T.E. A ribozyme-mediated, gene "knockdown" strategy for the identification of gene function in zebrafish. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 13777-13781
101. Yau E., and Sullivan J.M. Cell-based, high-throughput screening of rationally designed ribozymes. Invest. Ophthalmol. Vis. Sci. 47 (2006) 848
102. Yau E.H., and Sullivan J.M. High throughput cellular screening for ribozyme development against arbitrary mRNA targets. Invest. Ophthalmol. Vis. Sci. 48 (2007) 1681
103. Yau E.H., Kolniak T.A., Taggart R.T., Sheflin L.G., and Sullivan J.M. Optimization of lead ribozyme agents for human rod opsin therapeutics. Invest. Ophthalmol. Vis. Sci. 49 (2008) 5344
104. Young R.W., and Droz B. The renewal of protein in retinal rods and cones. J. Cell Biol. 39 (1968) 169-184
105. Young R.W. The renewal of photoreceptor cell outer segments. J. Cell. Biol. 33 (1967) 61-72
106. Zar J.H. Biostatistical Analysis. second ed. (1984), Prentice-Hall, Englewood Cliffs, NJ 718 pp.
107. Zoumadakis M., and Tabler M. Comparative analysis of cleavage rates after systematic permutation of the NUX↓ consensus target motif for hammerhead ribozymes. Nucleic Acids Res. 23 (1995) 1192-1196
108. Zuker M., and Sankoff D. RNA secondary structures and their prediction. Bull. Math. Biol. 46 (1984) 591-621
109. Zuker M. On finding all suboptimal foldings of an RNA molecule. Science 244 (1989) 48-52
110. Zuker M., Mathews D.H., and Turner D.H. Algorithms and thermodynamics for RNA secondary structure prediction: a practical guide. In: Barciszewski J., and Clark B.F.C. (Eds). RNA Biochemistry and Biotechnology. NATO ASI Series (1999), Kluwer Academic Publishers
111. Zuker M. Calculating nucleic acid secondary structure. Curr. Opin. Struct. Biol. 10 (2000) 303-310
112. Zuker M. Mfold Web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31 (2003) 3406-3415